Zai Lab Limited Stock Price, News & Analysis

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has engaged KPMG as its independent registered public accounting firm to facilitate compliance with U.S. audit requirements under the Holding Foreign Companies Accountable Act. This strategic move aims to ensure the company's continued listing on Nasdaq. The engagement of KPMG, based in the United States, will cover annual consolidated financial statements and internal controls over financial reporting for the fiscal year ending December 31, 2022. The transition was amicable, with no unresolved issues with the previous auditor.

Zai Lab Limited (NASDAQ: ZLAB) has announced it will report its financial results for Q1 2022 on May 10, 2022, following market close. The company will host a conference call and webcast on May 11, 2022, at 8:00 a.m. ET. Zai Lab is focused on developing therapies for unmet medical needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. It aims to become a leading global biopharmaceutical company through innovative product development and strategic partnerships.

Zai Lab Limited (NASDAQ: ZLAB) is set to present groundbreaking data on its oncology pipeline at the 2022 AACR Annual Meeting in New Orleans from April 8-13, 2022. Key highlights include the first preview of preclinical data for ZL-1218, an anti-CCR8 antibody targeting solid tumors, along with additional candidates like ZL-1201 and ZL-1211 for various cancers. The oral presentation will take place on April 12, 2022, showcasing promising therapeutic developments. Zai Lab emphasizes its commitment to advancing cancer treatments globally, addressing significant unmet medical needs.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced an extraordinary general meeting (EGM) to be held virtually on March 28, 2022, at 8:00 a.m. Eastern Time. This change is due to COVID-19 restrictions in Shanghai. Shareholders will vote on a proposal for a 1-to-10 share subdivision. Shareholders of record may attend the meeting virtually using a control number found on their proxy materials. The EGM format has been updated, but prior proxy materials remain valid for voting.

Zai Lab Limited (NASDAQ: ZLAB) presented Phase 3 PRIME study results at the Society of Gynecologic Oncology annual meeting, revealing that ZEJULA (niraparib) significantly improved progression-free survival (PFS) in patients with advanced ovarian cancer. The median PFS for niraparib was 24.8 months compared to 8.3 months for placebo. Treatment was well-tolerated, with a low discontinuation rate due to adverse events (less than 7%). This data supports niraparib as a standard maintenance therapy after platinum-based chemotherapy in China.

Zai Lab Limited (NASDAQ: ZLAB) announced the appointment of Josh Smiley as Chief Operating Officer (COO) effective August 1, 2022. With over 26 years of biopharmaceutical experience, he previously held leadership roles at Eli Lilly. CEO Dr. Samantha Du emphasized Smiley's leadership expertise as essential for Zai Lab's growth and operational excellence. His appointment comes during a pivotal time for Zai Lab, with significant opportunities in their pipeline aimed at expanding geographically and diversifying their financial base.

Zai Lab Limited (NASDAQ: ZLAB) reported strong financial growth for 2021, achieving net product revenues of $144.1 million compared to $49.0 million in 2020. Key drivers included a 200% increase in ZEJULA revenue and significant advancements in its product pipeline, including proof of concept for ZL-1102. R&D expenses increased to $573.3 million due to new licensing agreements and clinical trials. The company plans to submit new drug applications and expects substantial revenue growth, projecting peak-year sales of $2.5 to $3 billion by 2030.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced that its investigational drug repotrectinib received Breakthrough Therapy Designation from the NMPA for treating ROS1-positive metastatic non-small-cell lung cancer (NSCLC) in patients who haven't received ROS1 TKI treatment. The Phase 1/2 TRIDENT-1 study provided initial data supporting this designation. Repotrectinib targets ROS1 and NTRK mutations and may be the best-in-class therapy, offering hope for patients in need, especially in a region with high lung cancer incidence.

Zai Lab Limited (ZLAB) will announce its financial results for the year ended December 31, 2021, after U.S. market close on March 1, 2022. A conference call and webcast will be held on March 2, 2022, at 8:00 a.m. ET. Participants must register in advance to receive access details. Zai Lab is focused on developing therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience. The company aims to innovate and commercialize products addressing unmet medical needs globally.